Tagged with BI

Asia-Pacific The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of cannabis in Thailand; and the first Vietnamese coronavirus vaccine candidate’s Phase III trials.   Indonesia’s Kalbe Farma sales underwhelm investors…

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…

USA Taking the example of music’s effect on Alzheimer’s disease patients, John G Singer makes the case for a more holistic approach to healthcare; focusing less on the transformative potential of individual drugs and more on value as a stream of benefits delivered through a living system.   Singer/songwriter Glen Campbell,…

Switzerland Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in cancer research, the ways in which the firm’s funding strategy has evolved, and how its future growth trajectory might look.…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…

Switzerland Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the new generation of obesity treatments coming from Big Pharma. Moreover, he discusses EraCal’s development strategy and the Swiss biotech ecosystem.…

Saudi Arabia Bristol Myers Squibb’s General Manager for the Middle East and Africa (MEA) Oscar Delgado outlines the company’s pandemic journey, the big changes transforming the Saudi market, the challenges on regulatory data protection, and the opportunities to make Saudi Arabia a leader in clinical trials and innovation within the region.  …

China The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.   How Hong Kong can cement its position as a biotech listing hub (SCMP) https://www.scmp.com/comment/opinion/article/3134767/how-hong-kong-can-cement-its-position-biotech-listing-hub To maintain its growth and…

Ecuador The cannabis and hemp industry is an emerging new industry in Ecuador with the Reform of the Criminal Law, enacted on June 21st, 2020.   Included among the reforms is the decriminalization of possession of drugs containing cannabis or derivatives as their active ingredient for therapeutic, palliative, or medicinal use,…

Saudi Arabia Historically dependent on oil, Saudi Arabia, like most countries in the Arabian Peninsula, is now investing a large chunk of the sizeable resources obtained from fossil fuels in diversifying its economy. Pharmaceuticals, as one of the strategic sectors in the country’s diversification strategy, has reaped the benefits and the Saudi…

Saudi Arabia Haitham Habashi, general manager for Merck Saudi Arabia, outlines his affiliate’s approach to the big reforms shaping the country’s healthcare system, discusses the new public procurement process, and explains why Vision 2030 means transformative opportunities for Saudis, women, and health. Moreover, he highlights Merck’s manufacturing in Saudi Arabia and its…

Singapore Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and rich pipeline of clinical assets in global development.   As we are able to now understand biological systems much better…